GB1021924A - Improvements in or relating to method of preparing sustained release tablets - Google Patents

Improvements in or relating to method of preparing sustained release tablets

Info

Publication number
GB1021924A
GB1021924A GB1848063A GB1848063A GB1021924A GB 1021924 A GB1021924 A GB 1021924A GB 1848063 A GB1848063 A GB 1848063A GB 1848063 A GB1848063 A GB 1848063A GB 1021924 A GB1021924 A GB 1021924A
Authority
GB
United Kingdom
Prior art keywords
sustained release
stearate
calcium
salicylamide
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB1848063A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Smith Kline and French Laboratories Ltd
Original Assignee
Smith Kline and French Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smith Kline and French Laboratories Ltd filed Critical Smith Kline and French Laboratories Ltd
Publication of GB1021924A publication Critical patent/GB1021924A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F04—POSITIVE - DISPLACEMENT MACHINES FOR LIQUIDS; PUMPS FOR LIQUIDS OR ELASTIC FLUIDS
    • F04C—ROTARY-PISTON, OR OSCILLATING-PISTON, POSITIVE-DISPLACEMENT MACHINES FOR LIQUIDS; ROTARY-PISTON, OR OSCILLATING-PISTON, POSITIVE-DISPLACEMENT PUMPS
    • F04C2210/00—Fluid
    • F04C2210/26—Refrigerants with particular properties, e.g. HFC-134a

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Sustained release pharmaceutical tablets are prepared by admixing in a dry state a medicament and a comminuted, pharmaceutically acceptable, substantially water insoluble, sustained release, lipid material which has a melting point in the range of 40 DEG to 100 DEG C. and is resistant to disintegration and slowly dispersible in the gastrointestinal tract, said comminuted material having a particle size of from 10 to 1500 microns, and compressing the mixture so formed into a tablet. The mixture may include a filler and a lubricant; fillers specified are calcium carbonate, lactose, powdered sugar, kaolin, magnesium carbonate, barium sulphate, diatomaceous earth and calcium sulphate dihydrate, and as lubricants stearic acid, magnesium stearate, sodium stearate, calcium stearate, talc and sodium benzoate. Many types of waxes, fatty acid esters including glycerides, fatty acids and fatty alcohols are given as examples of the sustained release, lipid material; the preferred materials are hydrogenated castor oil, glyceryl monostearate, glyceryl distearate, 12-hydroxy-stearyl alcohol and microcrystalline wax. Specified medicaments are acetaminophen, acetyl salicylic acid, aminophylline, chlorpromazine, prochlorperazine maleate, salicylamide, secobartical, trans-2-phenylcyclopropylamine and tetracycline. In one Example, a sustained release tablet comprises acetaminophen and salicylamide together.
GB1848063A 1962-06-22 1963-05-09 Improvements in or relating to method of preparing sustained release tablets Expired GB1021924A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20460362A 1962-06-22 1962-06-22

Publications (1)

Publication Number Publication Date
GB1021924A true GB1021924A (en) 1966-03-09

Family

ID=22758617

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1848063A Expired GB1021924A (en) 1962-06-22 1963-05-09 Improvements in or relating to method of preparing sustained release tablets

Country Status (2)

Country Link
DE (1) DE1492123A1 (en)
GB (1) GB1021924A (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2374900A1 (en) * 1975-12-08 1978-07-21 Procter & Gamble PRODUCT FOR IMMEDIATE AND ORDERED COMPOUNDS RELEASE
US4880830A (en) * 1986-02-13 1989-11-14 Ethical Pharmaceuticals Limited Slow release formulation
US5879714A (en) * 1996-04-24 1999-03-09 Bernard Charles Sherman Controlled-release pharmaceutical compositions
EP1681061A1 (en) * 2005-01-11 2006-07-19 Jobes Vital GmbH Composition for treating apnea, snoring and sleep disorders

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2471784A1 (en) * 1979-12-21 1981-06-26 Roussel Uclaf EXTENDED ACTION ANTIARRHYTHMIC DRUGS WITH THE ACTIVE INGREDIENT AS A / 2- / BIS (1-METHYLETHYL) AMINO / ETHYL / -A-PHENYL-2-PYRIDINE ACETAMIDE OR SALTS THEREOF, AND THE PROCESS FOR THE PREPARATION OF THESE MEDICAMENTS AND COMPOSITIONS INCLUDING THEM
DE3024416C2 (en) * 1980-06-28 1982-04-15 Gödecke AG, 1000 Berlin Process for the production of medicaments with sustained release of active substances
WO1982004392A1 (en) * 1981-06-18 1982-12-23 Uclaf Roussel Method of preparing pharmaceutical compositions containing alpha-/2-/bis(1-methylethyl)amino/ethyl/alpha-phenyl 2-pyridine acetamide or one of its salts
FR2573307B1 (en) * 1984-11-22 1988-06-10 Virbac Ctre Rech Biolog EXTENDED RELEASE ANABOLIZING IMPLANTS

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2374900A1 (en) * 1975-12-08 1978-07-21 Procter & Gamble PRODUCT FOR IMMEDIATE AND ORDERED COMPOUNDS RELEASE
US4880830A (en) * 1986-02-13 1989-11-14 Ethical Pharmaceuticals Limited Slow release formulation
US5879714A (en) * 1996-04-24 1999-03-09 Bernard Charles Sherman Controlled-release pharmaceutical compositions
EP1681061A1 (en) * 2005-01-11 2006-07-19 Jobes Vital GmbH Composition for treating apnea, snoring and sleep disorders

Also Published As

Publication number Publication date
DE1492123A1 (en) 1969-07-17

Similar Documents

Publication Publication Date Title
US4983399A (en) Direct compression carrier composition
US4540566A (en) Prolonged release drug dosage forms based on modified low viscosity grade hydroxypropylmethylcellulose
EP0322222B1 (en) Sustained release drug dosage forms containing hydroxypropylmethylcellulose and alkali metal carboxylates
GB1030127A (en) Improvements in or relating to method of preparing sustained release pharmaceutical pellets and product thereof
US4795327A (en) Controlled release solid drug dosage forms based on mixtures of water soluble nonionic cellulose ethers and anionic surfactants
US6258381B1 (en) Tablet and process for making the same
US7323192B2 (en) Immediate release tablet
US3146169A (en) Pharmaceutical formulations and their manufacture
US3279998A (en) Method of preparing sustained release tablets
US20110142931A1 (en) Soft tablet containing dextrose monohydrate
US7052706B2 (en) Control release formulation containing a hydrophobic material as the sustained release agent
KR890015733A (en) Antacid composition with long-term gastric retention time
US3632778A (en) Tablets containing l-dopa
EP0213761A2 (en) Stable sodium aspirin tablet compositions
GB1021924A (en) Improvements in or relating to method of preparing sustained release tablets
KR20150042289A (en) Solid pharmaceutical preparation containing levothyroxine
KR20070119654A (en) Pharmaceutical composition
JPWO2008044331A1 (en) Solid formulation containing ibuprofen and tranexamic acid
US20040081695A1 (en) Dosage forms having an inner core and an outer shell
JP2007161588A (en) Solid dispersion of fenofibrate and therapeutic agent for hyperlipemia containing the dispersion
RU98123101A (en) The pharmaceutical compositions and pharmaceutical preparations containing potassium, sodium and Tris oxaprozin salt formulations, their application to eliminate or reduce pain in a mammal for the treatment of inflammation and disorders associated with inflammation in mammals, the production process of pharmaceutical preparations
US4908210A (en) Lactylic salt tablet formulations and tablets
GB1031146A (en) Method of preparing sustained release pharmaceutical tablets
CA2071262C (en) Stabilized solid dosage forms of choline metal carboxymethylcellulose salicylate compositions
JPS6321649B2 (en)